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Abstract: The evaluation of pain and the subsequent issue of pain control is a clinical challenge 
that all healthcare providers face. Pain in the elderly population is especially difﬁ  cult given the 
myriad of physiological, pharmacological, and psychological aspects of caring for the geriatric 
patient. Opiates are the mainstay of pain treatment throughout all age groups but special atten-
tion must be paid to the efﬁ  cacy and side effects of these powerful drugs when prescribing to a 
population with impaired metabolism, excretion and physical reserve. In a random chart review 
of 300 US veterans, 44% of those receiving an analgesic also received opioids. The increasing 
use of opiates for pain management by healthcare practitioners requires that those prescribing 
opioids be aware of the special considerations for treating the elderly. This article will address 
the precautions one must take when using opiates in the geriatric population, as well as the side 
effects and ways to minimize them.
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Introduction
The prevalence of pain in older adults is high. The care of older adults can occur in 
varied settings ranging from independent living to long term care and palliative care. 
Studies report the prevalence of pain in community-dwelling elderly at 25%–50% 
and for nursing home residents as high as 70% (Ferrell 2003). The American Geriat-
rics Society (AGS) panel on persistent pain in older persons states that up-to 80% of 
long-term care residents have substantial pain (AGS 2002), and 25% of those received 
neither analgesic medication nor nonpharmacological treatment for their pain (Won 
et al 2004). It is important to assess for pain, evaluate, treat, and recognize side effects 
that may be associated with the pharmacologic management of pain in older adults. 
This can be very challenging due to the alterations in opiate pharmacokinetics which 
occur with normal physiologic aging. Other common problems that should be taken 
into consideration when caring for older adults include polypharmacy, multiple com-
orbities, and the potential of more side effects or treatment failures (Linnebur et al 
2005). It is important for those clinicians who provide care for elderly to have training 
in the recognition of pain and the subtle behaviors associated with those patients who 
may be in pain but are unable to communicate.
Many geriatricians provide care to elderly patients as part of a palliative care 
treatment plan. According to the World Health Organization palliative pain manage-
ment ladder, patients with moderate to severe pain should receive opioid analgesics 
as the mainstay of treatment (WHO 2006). Opiates are indicated for management 
of both acute and chronic pain, as well as for the different classes of pain such as 
nociceptive and neuropathic pain. Meta-analysis done by Furlan and colleagues 
(2006) regarding effectiveness and side effects of opioids for chronic noncancer 
pain concluded that opioids have better outcome than placebo in reducing pain and 
improving functional activities, as well as being more effective for both nociceptive 
and neuropathic pain. Opiates are commonly used in clinical care. A review of 300 
randomly selected charts among the US veterans population noted that approximately Clinical Interventions in Aging 2008:3(2) 274
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75% of patients with chronic pain were prescribed at least 
1 analgesic, and most received 2 or more. While nonste-
roidal anti-inﬂ  ammatory drugs (NSAID) were the most 
commonly prescribed class of analgesics, 44% of those 
receiving an analgesic also received opioids (Clark 2006). 
The American Geriatrics Society (AGS) 2002 Guidelines 
for the Management of Persistent Pain in Older Adults 
recommendations included simplifying the pain regimen, 
avoiding polypharmacy, and beginning drugs at lower 
dosages and titrating upward as needed (AGS 2002). The 
guidelines also stressed the unacceptable risks associated 
with nonselective NSAID use in elderly due to gastrointes-
tinal bleeding and new revisions by the AGS panel will be 
developed due to the withdrawal of some COX-2 from the 
US market. These guidelines also refer to opiates as pos-
sibly being appropriate in severe pain (AGS 2002). Thus, 
it is imperative that providers be knowledgeable in the use 
of opiates and their side effects.
Physiologic changes with aging
Opiates are highly varied, however except for fentanyl and 
methadone, it is generally thought that they possess similar 
pharmacokinetic activity. In general young adults, opiates 
are rapidly absorbed in the gut, have high rate of ﬁ  rst pass in 
the liver, are conjugated in the liver, have metabolites, and 
vary in distribution based on their differing protein afﬁ  nity, 
and then are excreted via bile to feces or via kidneys. It is 
important to understand normal age-associated changes in 
the pharmacokinetic and pharmacodynamic action of drugs. 
Pharmacodynamic affects are complex and depend upon 
poorly measured variables such as receptor function and 
intracellular response which can alter drug action (Hughes 
1998). Pharmacokinetic actions of drug absorption, distri-
bution, and elimination are more measurable. In general, 
the rate at which certain drugs are absorbed can be altered 
in the elderly because of decreased gastrointestinal transit 
time and increased gastric pH secondary to use of proton 
pump inhibitors, H2 receptor antagonist, or antacids. With 
aging, there are changes in body composition: increase in 
adipose tissue, decrease in lean body mass and decrease in 
total body water. These changes can affect drug distribution. 
Therefore, lipophilic drugs tend to have greater volume of 
distribution, and it can take more time to be eliminated from 
the body (Linnebur et al 2005). Aging can also bring reduc-
tion in hepatic blood ﬂ  ow and volume which can decrease 
metabolism of drugs (Tegeder et al 1999; AGS 2006). 
Additional impairments in drug metabolism can occur 
with impaired Phase I reactions which include oxidation, 
hydroxylation, and dealkylation (Tegeder et al 1999). This 
can speciﬁ  cally reduce the ﬁ  rst pass affect of opiates in 
elderly (Tegeder et al 1999). Elimination of drugs can be 
altered with age related reductions in renal blood ﬂ  ow and 
glomerular ﬁ  ltration rate. For opiates that have primary 
renal clearance, such as morphine and hydromorphone, 
decreases in GFR lead to more side effects (Davies et al 
1996). The above changes generally cause drugs used in 
elderly to be more potent and have a longer duration of 
action than predicted.
Because of pharmacokinetic and pharmacodynamic 
changes with aging, opioids should be started at the lower 
dose, about 25%–50% of the dose given to younger patients 
(Clark 2001). Opioids that should be avoided in the older 
patients include meperidine, propoxyphene, and tramadol. 
Meperidine has active metabolites which can cause neuro-
excitation, nervousness, and seizures. Prophoxyphene has 
not been shown to be more effective than placebo. Tramadol 
is not recommended in patients who are taking serotonergic 
medications or in those with underlying seizure disorders. 
Tramadol binds to opioid receptors and inhibits the reuptake 
of both norepinephrine and serotonin (AGS 2006). Codeine 
can be used, however there should be recognition that there 
is individual variability in its effectiveness dependent upon 
drug metabolism into its seven active metabolites. Up to 
30% of the population has been reported to be poor (PM) 
hydroxylators of debrisoquine required for Codeine activation 
(Yue et al 2001).
Commonly used opiates
Oral opioid medications are the most commonly prescribed 
medications in palliative care and geriatrics. Step 2 opiates 
of the WHO ladder generally consist of combination opiates 
containing hydrocodone, oxycodone with acetaminophen, or 
NSAIDs. These have ceiling limits based on the toxicity of 
the acetaminophen- or NSAID-dosing. Short-acting agents 
like oral morphine, hydromorphone, oxycodone, and codeine 
are used alone or in combination with acetaminophen, aspirin 
(ASA), or ibuprofen. Peak analgesic effect occurs within 60 
minutes and the effect lasts for 2–4 hours in patients with 
normal renal function. These medications can be dosed at a 
4-hour interval if given alone or 6-hour intervals if used in 
combination (APM 1992; PDR 2007; Thomson 2007).
It is important to understand that patients do not notice a 
change in analgesic effects if dosage increases are less than 
25% over baseline. Commonly used practice guidelines 
include increasing dose by 50%–100% in patients with 
moderate to severe pain, irrespective of starting dose, and Clinical Interventions in Aging 2008:3(2) 275
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25%–50% in patients with mild to moderate pain (EPERC 
2007). Keep in mind that when using long-acting opioid 
medications or infusions, do not increase infusion basal rate 
more than 100% at any one point, irrespective of how many 
bolus/breakthrough doses have been used in patients with 
normal renal and hepatic functions. For elderly patients, 
and for those with renal/hepatic dysfunction, dose escala-
tion percentages should be reduced. Dose escalation always 
depends on half life of the medications. Short-acting oral 
single agent opioids, can be safely escalated every 2 hours. 
Sustained release oral opioids can be escalated every 24 
hours. For fentanyl patch, methadone or levorphanol, no 
earlier than 72 hours is recommended (Weissman et al 1996, 
1999; Hanks et al 2005).
Although the AGS pain panel (2002) recommends around 
the clock pain control versus “on demand” methods, there 
maybe appropriate needs for using as needed orders (PRN). 
When using PRN orders, it is important to use these orders 
in a range to provide options, but narrow enough to ensure 
safety, keeping in mind renal/hepatic functions of the indi-
vidual patients. The difference should be no more than 4 
times the lowest dose. It is also important to acknowledge 
patient’s exposure to opioids. In opioid naïve patients, the 
lowest dose is recommended as opposed to patients who have 
received prior opioids with inadequate pain relief where a 
higher dose is justiﬁ  ed. In the older population, start low and 
go slow monitoring side effects and pain tolerance. Debili-
tated patients or those with respiratory insufﬁ  ciency are more 
at risk for hypoxia if over sedated. It is important to take into 
consideration, the patient’s needs and involve families and 
close loved ones when making decisions and when providing 
education about opiates. It is also a useful tool to document 
patient response to PRN dosing so as to more accurately 
tailor their pain regimen (Gordon et al 2004).
Opiate equianalgesic potency tables are not precise and 
vary slightly based on the source; they should be used only 
as guides. Commonly reported equianalgesic tables include 
the following (short acting formulations, oral) (VA/DoD 
2007):
1.  Morphine 30 mg
2. Oxycodone  15–30  mg
3.  Hydrocodone 30 mg
4. Hydromorphone  7.5  mg
5. Codeine  180–200  mg
6.  Methadone is highly variable depending on previous opi-
ate dose
A new opiate to the market in 2006 is oxymorphone. 
Oral oxymorphone IR/ER tablet formulations are a 
semisynthetic opioid receptor agonist structurally similar to 
hydromorphone. Elderly patients can have increased plasma 
levels and systemic effects (Guay 2007). Few studies pub-
lished on the equianalgesic potency of oxymorphone report 
that it has an equianalgesic dose ratio of 2:1 compared with 
oxycodone (Gabrail et al 2004).
When converting from one opiate to another, the new 
opiate should be given at 50% to 67% of the calculated dose 
for all opiates, except fentanyl and methadone, to allow for 
incomplete cross-tolerance. Cross-tolerance effects can cause 
the new opiate to have more adverse effects and analgesic 
properties. Conversion to fentanyl should be based on the 
manufacturer guidelines. Methadone conversion should be 
done by experienced providers as the relationship is non 
linear to the prior dose of opiates (Chau and Mason 2005).
Treatment goals
•  Pain control with limited side effects
•  Around the clock dosing
•  As needed for breakthrough pain
  ¶   Avoidance of polypharmacy and multiple drug agents. 
It is preferred that one opiate be used and titrated 
to effect instead of multiple small doses of varying 
opiates. As elderly take many concomitant drugs, 
prescribers of opiates should also recognize potential 
drug interactions such as antifungals and methadone 
that can lead to elevated levels of opiates and toxicity 
(Thomson 2007).
  ¶   ARecognition of pain triggers, particularly among 
cognitively impaired elderly. In cognitively impaired 
residents, activities or treatments that have caused 
pain in the past should be anticipated as causing 
pain in the future. Pain should also be anticipated: 
cognitively impaired elders should be premedicated 
(Hutt et al 2007).
  ¶   Adual therapy targeted towards the individual pain 
assessment, with recognition of the following:
  1.    American Pain Society (Miaskowski et al 2005) 
and AGS (2002) both emphasize the importance 
of obtaining the patients’ self-report of pain when-
ever possible.
  2.   Dementia is prevalent and may impair the percep-
tion of pain, ability to report pain, ability to recall 
pain sensation for evaluating relief, and the ability 
to communicate about relief. Thus, the potential 
for unrelieved and unrecognized pain is greater 
among those who cannot reliably evaluate and/or 




Furlan and colleagues (2006) did a meta-analysis of effective-
ness and side effects of opioids and found that nausea was 
the most signiﬁ  cant side effect 14% (95% Conﬁ  dence inter-
val 4%–25%). The mechanism of action of opioid-induced 
nausea is through the direct stimulation on chemoreceptor 
trigger zone (CTZ), which detects noxious chemicals in the 
blood and sends signals to the vomiting center (VC) in the 
medulla and initiates the vomiting reﬂ  ex. The other mecha-
nisms are through the direct stimulation of the vestibular 
apparatus and anticholinergic effects on the gastrointestinal 
system (Gordon et al 2004).
Constipation
Opioid peptides and opioid receptors are distributed along 
the gastrointestinal (GI) tract, indicating endogenous opiates 
released peripherally may modulate GI motor and secretory 
functions. Most opiates that have a selective or predominant 
mu agonist activity inhibit gastric motility and delay gastric 
emptying by acting centrally; delta and kappa agonist are 
inactive when injected systemically. This increase in colonic 
motility and the delay in colonic transit are associated with a 
reinforcement of tonic contractions and reduced propulsive 
waves. This in turn leads to opiate induced constipation 
(Bueno and Fioramonti 1988).
Walsh (1984) conducted studies regarding opiate-induced 
constipation in hospice patients in Florida and found that 40% 
to 64% of hospice patients with cancer have been found to 
have constipation. Walsh also concluded that constipation is 
the most common side effect of morphine in hospice patients 
with a prevalence of 48% and it impacted negatively on qual-
ity of life. Management of constipation is important in patients 
who are taking opioids which can sometimes lead to serious 
complications. Unlike other side effects of opioids, there is 
no tolerance effect on constipation, so treatment of constipa-
tion should be initiated preventively at the same time when 
opioid therapy is started. Combined use of stool softeners and 
stimulant laxatives are recommended (Walsh 1984).
Urinary retention
Urinary retention is the anticholinergic side effect of opioids 
and can be secondary to opioid-induced constipation (Meier 
et al 1998).
Central nervous system adverse effects
Sedation and mild cognitive impairment are the other com-
mon side effects of opioids in elderly (Hayes et al 2007). 
Combinations of opioids and other central nervous system 
(CNS) depressant drugs such as barbiturates, benzodiaz-
epines, antidepressants, and antipsychotics may have additive 
effects on sedation. Since most of the elderly are on poly-
pharmacy, a careful review of medications is crucial while 
they are on opioid therapy (Cherny et al 2001). Myoclonus 
is the other CNS adverse effect and occurs in patients with 
chronic opioid therapy. It appears to be dose related and more 
common with oral morphine than parenteral which suggests 
it may be due to a production of morphine metabolites by the 
liver (Cherny et al 2001).
Pruritis
Pruritis develops in about 2%–10% of patients with opioid use 
(Cherny et al 2001). This generally resolves within one week.
Respiratory depression
The agonist activity of opioids at the µ-opiate receptors is 
very important clinically in the alleviation of pain. However; 
it is also the cause of an unwanted side effect which is the 
marked depression of breathing that can complicate their 
clinical administration and be potentially life threatening 
when opiates are abused (McCrimmon and Alheid 2003). 
The degree of respiratory depression depends upon the serum 
level of opioids. First, patients become somnolent, and then 
they become less arousable and ﬁ  nally obtunded. The pat-
tern of respiration becomes shallower and slower. Naloxone 
is the opioid receptor antagonist and is not recommend for 
use until the patient’s respiratory rate is less than 8 breaths 
per minute or the oxygen saturation is less than 90%. This 
is done to avoid pain crisis and acute withdrawal symptoms 
(Ferrell 2003; AGS 2006).
Opioid-induced hyperalgesia
Patients who are receiving increasing doses of opioids may 
have opioid-induced hyperlagesia. This is the phenomenon 
of increasing sensitivity to both pain (hyperlagesia) and 
nonpainful stimuli (allodynia). The mechanism of action is 
due to toxic metabolites of opioid (morphine-3-glucuronide 
(M3G) or hydromorphone-3-glucronide (H3G), activation of 
N-metyl-D-asparate (NMDA) receptors in the CNS. Since 
it is due to the effect of toxic metabolites, the other opioid 
hyper excitability effects such as myoclonus, delirium or 
seizures can also be present (Kranz et al 2003).
Cardiovascular system
QT prolongation and torsades de pointes were found to 
take place in individuals infected with HIV and treated Clinical Interventions in Aging 2008:3(2) 277
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with methadone (Clark 2001). Methadone dose correlated 
positively with the QTc interval prolongation. This ﬁ  nding 
supports the possibility that methadone contributed to the 
development of arrhythmias (Gil et al 2003).
Endocrine
Opioids have effects on two levels in the endocrine system: 
hypothalamic-pituitary-adrenal axis and also on the 
hypothalamic-pituitary-gonadal axis resulting in reduced 
serum luteinizing hormone, cortisol levels and increased 
prolactin levels (Ballantyne and Mao 2003). Diminished bone 
density, decreased libido and impaired sexual performance 
are reported with chronic opiate use. Heroin use results 
in acute suppression of luteinizing hormone (LH) release 
from the pituitary followed by a secondary drop in plasma 
testosterone levels (Mirin et al 1980).
Management of opioid side effects
The recommendations from The European Association of 
Palliative Care (EAPC) Research Network for management 
of opioid side effects include:
1. Dose  reduction
2.  Symptomatic management of the adverse effects using 
drugs targeting the symptoms
3. Opioid  rotation
4.  Switching the route of administration.
If pain is well controlled, but there are adverse effects, 
a reduction in dose of opioids gradually will help in resolv-
ing the adverse effects while maintaining pain relief. Some 
adverse effects such as drowsiness, delirium, and myoclonus 
occur in direct relation to the dose which may be reversed by 
dose reduction. The recommend dose reduction is 25%–50%. 
If the dose reduction interferes with efﬁ  cacy of pain control, 
it is recommended to add adjuvant therapy such as steroids, 
neurontin, or low dose tricyclic antidepressants (Cherny 
et al 2001).
Conclusion
Although pain management can be subjective and fraught 
with potential adversity, the goal for all healthcare provid-
ers should be to control patients’ pain while limiting side 
effects. Knowledge about pain therapy can assist in achiev-
ing the goals of pain management. The elderly population 
is especially challenging when one has to consider all of the 
pharmacodynamic changes that occur with normal aging. 
The side effect proﬁ  le of opiates is similar for all age groups; 
however the elderly population is at a greater risk for these 
side effects given their comorbidities and high incidence 
of polypharmacy. Using opiates appropriately and at the 
most efﬁ  cacious dosage for the severity and type of pain 
becomes crucial in the elderly. Knowing how to increase 
medications and to move between the different classes is 
also necessary in the safe and successful management of 
pain. Adjuvant therapy with other nonopioid pain relievers 
should be encouraged and in fact a standard practice in pain 
management. Properly evaluating and treating pain in all 
types of elderly patients and clinical scenarios should be the 
goal of all clinicians.
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